Nektar Grants Stock Options to New Employees Under Inducement Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy NKTR?
Source: Yahoo Finance
- Stock Option Grant: On February 20, 2026, Nektar Therapeutics granted 4,300 non-qualified stock options to three newly hired employees, with an exercise price of $73.73 per share, reflecting the closing price on that date, aimed at attracting top talent to the company.
- Inducement Plan Background: The stock option grant is based on Nektar's 2025 Inducement Plan adopted on November 6, 2025, designed exclusively for individuals who were not previously employed by the company, in compliance with Nasdaq Listing Rule 5635(c)(4), to facilitate talent acquisition.
- Option Grant Terms: These stock options have an eight-year term and will vest over four years, with 1/4 of the shares vesting on the one-year anniversary and 1/48 vesting monthly thereafter, ensuring employee retention by linking vesting to continued employment.
- Strategic Importance: By implementing this incentive measure, Nektar not only enhances its appeal to new employees but also demonstrates its competitiveness in the biotechnology sector, aiming to accelerate innovation and market expansion within its R&D pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.150
Low
102.00
Averages
123.43
High
165.00
Current: 69.150
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: A shareholder has filed a class action lawsuit on behalf of investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, alleging misrepresentations regarding the Phase 2b trial for REZOLVE-AA, which may have led to investor losses.
- Lawsuit Details Revealed: The lawsuit, initiated by Bernstein Liebhard LLP, requires investors wishing to serve as lead plaintiffs to file necessary documents by May 5, 2026, indicating their representative status in the litigation.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, showcasing its significant influence in the legal field.
- Transparent Fee Structure: All representation in this lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses, ensuring minimal financial burden for all investors participating in the litigation.
See More
Class Action Lawsuit Filed Against Nektar Therapeutics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, indicating potential misleading statements that could undermine investor confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, suggesting a risk-free remedy for affected investors and potentially increasing participation in the lawsuit.
- Details of Allegations: The lawsuit claims that Nektar failed to adhere to applicable standards in the REZOLVE-AA trial, raising concerns about the integrity of the trial results, which could negatively impact the company's future prospects and market performance.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California on behalf of investors who purchased securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that trial enrollment did not adhere to applicable standards, which could significantly impact trial outcomes and investor confidence.
- Investor Action Deadline: Investors have until May 5, 2026, to apply to be appointed as Lead Plaintiff in the class action, underscoring concerns regarding corporate governance and transparency in Nektar's operations.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Allegation: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial results, while the company overstated the integrity of the trial, resulting in misleading public statements.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered damages, highlighting significant failures in the company's disclosure practices, which could lead to stock price declines and affect future investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, involving shareholders who purchased shares from February 26, 2025, to December 15, 2025, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA study, likely negatively impacting trial results, suggesting that the company's public statements were false and misleading throughout the class period, which could undermine investor confidence.
- Investor Participation Opportunity: Shareholders who suffered losses are encouraged to contact DJS Law Group to participate in the lawsuit and potentially serve as lead plaintiffs, indicating that the company faces potential financial liability risks that could affect its stock performance.
- Legal Service Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, emphasizing its legal services for large hedge funds and alternative asset managers, showcasing its expertise and market influence in handling complex legal matters.
See More
Class Action Lawsuit Announced for Nektar Therapeutics
- Class Action Initiation: Rosen Law Firm announces a class action lawsuit against Nektar Therapeutics for securities purchasers between February 26, 2025, and December 15, 2025, indicating potential investor losses due to misleading statements.
- Compensation Structure: Investors joining the lawsuit may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights.
- Allegations Details: The lawsuit claims that Nektar failed to adhere to applicable standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and potentially impacting the company's reputation and stock price negatively.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Nektar Therapeutics Faces Class Action Lawsuit from Shareholders
- Class Action Initiated: A shareholder has filed a class action lawsuit on behalf of investors who purchased Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025, and December 15, 2025, alleging misrepresentations regarding the Phase 2b trial for REZOLVE-AA, which may have led to investor losses.
- Lawsuit Details Revealed: The lawsuit, initiated by Bernstein Liebhard LLP, requires investors wishing to serve as lead plaintiffs to file necessary documents by May 5, 2026, indicating their representative status in the litigation.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, showcasing its significant influence in the legal field.
- Transparent Fee Structure: All representation in this lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses, ensuring minimal financial burden for all investors participating in the litigation.
See More
Class Action Lawsuit Filed Against Nektar Therapeutics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, indicating potential misleading statements that could undermine investor confidence.
- Compensation Structure: Investors may receive compensation without any out-of-pocket costs through a contingency fee arrangement, suggesting a risk-free remedy for affected investors and potentially increasing participation in the lawsuit.
- Details of Allegations: The lawsuit claims that Nektar failed to adhere to applicable standards in the REZOLVE-AA trial, raising concerns about the integrity of the trial results, which could negatively impact the company's future prospects and market performance.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Nektar Therapeutics in the Northern District of California on behalf of investors who purchased securities between February 26, 2025, and December 15, 2025, seeking damages for violations of federal securities laws.
- Trial Results Disappoint: On December 16, 2025, Nektar announced that its REZOLVE-AA trial failed to achieve statistical significance, resulting in a 7.77% drop in stock price, equating to a loss of $4.14 per share, highlighting potential issues in the company's clinical trial processes.
- Allegations of Misrepresentation: The complaint alleges that Nektar executives made materially false and misleading statements during the class period, failing to disclose that trial enrollment did not adhere to applicable standards, which could significantly impact trial outcomes and investor confidence.
- Investor Action Deadline: Investors have until May 5, 2026, to apply to be appointed as Lead Plaintiff in the class action, underscoring concerns regarding corporate governance and transparency in Nektar's operations.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 26, 2025, and December 15, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Allegation: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA trial, leading to patient enrollment issues that could negatively impact trial results, while the company overstated the integrity of the trial, resulting in misleading public statements.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to reach out to discuss their rights, emphasizing its specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
- Market Reaction Impact: As the market learned the truth about Nektar, investors suffered damages, highlighting significant failures in the company's disclosure practices, which could lead to stock price declines and affect future investor confidence.
See More
Nektar Therapeutics Faces Class Action Lawsuit
- Class Action Reminder: DJS Law Group alerts investors of a class action lawsuit against Nektar Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, involving shareholders who purchased shares from February 26, 2025, to December 15, 2025, indicating significant legal risks for the company.
- False Statement Allegations: The complaint alleges that Nektar failed to adhere to protocol standards in its REZOLVE-AA study, likely negatively impacting trial results, suggesting that the company's public statements were false and misleading throughout the class period, which could undermine investor confidence.
- Investor Participation Opportunity: Shareholders who suffered losses are encouraged to contact DJS Law Group to participate in the lawsuit and potentially serve as lead plaintiffs, indicating that the company faces potential financial liability risks that could affect its stock performance.
- Legal Service Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, emphasizing its legal services for large hedge funds and alternative asset managers, showcasing its expertise and market influence in handling complex legal matters.
See More
Class Action Lawsuit Announced for Nektar Therapeutics
- Class Action Initiation: Rosen Law Firm announces a class action lawsuit against Nektar Therapeutics for securities purchasers between February 26, 2025, and December 15, 2025, indicating potential investor losses due to misleading statements.
- Compensation Structure: Investors joining the lawsuit may receive compensation without any out-of-pocket fees, highlighting the accessibility of legal services and the protection of investor rights.
- Allegations Details: The lawsuit claims that Nektar failed to adhere to applicable standards in the REZOLVE-AA trial, raising concerns about the trial's integrity and potentially impacting the company's reputation and stock price negatively.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
